Introduction
Familial Mediterranean fever (FMF) is an inherited autoinflammatory disease. The prevalence of FMF in Middle Eastern populations and other ethnic groups living around the Mediterranean basin, such as Jews, Armenians, Turks, and Arabs, is 1/200-1/1000 (1, 2) . The clinical manifestations include recurrent, self-limiting episodes of fever and painful polyserositis, particularly peritonitis, pleuritis, and arthritis; nausea and vomiting; common weakness; and chest and joint pain (3, 4) .
In the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5), female sexual dysfunction (FSD) includes sexual interest/arousal disorder, orgasmic disorder, genito-pelvic pain/penetration disorder, substance/medication-induced sexual dysfunction, and other specified and unspecified sexual dysfunctions (5) . It is a highly prevalent problem that is often underestimated in the general population (6) .
Another common clinical presentation in women with FMF is premenstrual symptoms (7) , which is defined as a set of affective, cognitive, and physical symptoms during the premenstrual phase of the menstrual cycle (8) . The most common premenstrual symptoms are low mood, tension, bouts of anger or irritability, mood swings, headache, abdominal distention, and appetite and sleep disturbances (9) . Its prevalence has been reported as 3%-8% (10, 11) .
Studies have shown that chronic rheumatic diseases negatively affect female sexual function and premenstrual symptoms (12, 13) . The drugs used in the treatment of chronic rheumatic diseases, the pathogenesis of the rheumatic disease, and disease-caused psychosocial factors can trigger new cases of premenstrual symptoms and FSD or aggravate existing cases (14, 15) . Female sexual function has not been studied sufficiently in patients with FMF, and there are few studies regarding the relationship between FMF and premenstrual syndrome. As such, the aim of this study was to investigate the effects of FMF and depression/anxiety associated with FMF on female sexual function and premenstrual symptoms. (Table 1) . Other research inclusion criteria were as follows: 18-50 years of age, married or sexually active. The exclusion criteria of the research were the presence of abdominal pain attack, comorbid medical conditions, diagnosis of psychiatric disorder in the previous 6 months, and regular use of drugs or substances other than colchicine or contraception medication. Thirty-three healthy volunteers matched for age and education level (education levels were determined according to the last schools from which they graduated) were recruited using the same criteria.
Materials and methods
Severity of depression and anxiety, which are considered to have an impact on sexual function, and premenstrual symptoms were determined by a scale. The severity of premenstrual symptoms and sexual dysfunction were evaluated by the same method. All scales were self-report questionnaires and were introduced to the participants before being filled out. The scales were applied in an appropriate environment considering the privacy of the participants and participants were given up to 30 min to complete them. The theory about the relationship between these measured variables and FMF was statistically tested.
Data collection instruments

Beck Depression Inventory (BDI)
This scale was developed by Beck in 1961 to determine risk of depression and to assess the level and severity of changes in depressive symptoms. A Turkish validity and reliability study of the BDI was conducted in 1988 by Hisli. The scale contains 21 items, and each item is assigned a score of 0-3 based on four self-assessment options (17,18).
Beck Anxiety Inventory (BAI)
This scale, developed by Beck and colleagues, is a self-rating scale used to determine the severity of anxiety symptoms. This scale consists of 21 items and it is scored on a Likerttype scale of 0-3. A Turkish validity and reliability study of the BAI was conducted in 1998 by Ulusoy et al. (19) .
Premenstrual Assessment Form (PAF)
This 95-item self-report scale is used to measure emotional, behavioral, and physical changes that might occur during the premenstrual period. The PAF was developed by Halbreich et al. (20) , and a Turkish validity and reliability study was conducted by Dereboy et al. (21) . The PAF was used to assess the severity of premenstrual symptoms. 
Statistics
The statistical significance threshold was considered to be P < 0.05. The distribution of variables was assessed by the Shapiro-Wilks test and the Mann-Whitney U test was used for comparisons. A model was created describing the effects of FMF on anxiety, depression, PMS, and sexual function. The significance of the model was examined by path analysis. The effect size was calculated by considering group means, assuming alpha of 0.05 and power of 0.80.
In the path analysis, we examined how sexual function, anxiety, depression, and PMS are associated with FMF. Path analysis can be used to describe the effects of exogenous variables (group and depression) on endogenous (vaginismus, frequency, anxiety, PMS) variables directly, indirectly, and by the sum of these variables. Path analysis enables an easy understanding of these effects by visualization in a path diagram. Exogenous variables in the model are those that are not explained by any variable. Endogenous variables in the model are those that are explained by exogenous variables or other endogenous variables (anxiety was both endogenous and exogenous in our study) (24, 25) . Path analysis can predict that the equations system determines all causal links in a variables system, solves complex relationships between variables, and clearly reveals the strength of the relationship (26) . Suhr stated that if a path coefficient value is smaller than 0.10, there is the presence of a weak effect; if a path coefficient value is between 0.10 and 0.50, there is the presence of a moderate effect; and if a path coefficient value is greater than 0.50, there is the presence of a strong effect (27).
Results
There were no statistically significant differences between the groups in terms of age and educational level (age: M FMF = 38.5, SD FMF = 6.9, M Controls = 36.3, SD Controls = 6.1, t(68) = 1.405, P = 0.165; education: χ 2 (2) = 0.648, P = 0.723). All of the FMF patients in this study had been using colchicine. The mean duration of colchicine use was 5.9 ± 7.1 years. Thirteen of the patients with FMF (36.1%) were using colchicine at 1 mg/day and 23 of the patients with FMF (63.9%) were using colchicine at 1.5 mg/day. We did not find a significant difference between patients with FMF using colchicine at 1 mg/day and patients with FMF using colchicine at 1.5 mg/day in terms of BAI, BDI, PAF, and GRISS total and subscale scores. We found statistical differences between groups in terms of BAI total score, PAF total score, GRISS total score, and frequency and vaginismus scores (subscales of GRISS). There were no differences between groups in terms of BDI total score or GRISS communication, satisfaction, touch, avoidance, and anorgasmia subscale scores. Comparisons between the total scale and subscale scores of the groups are shown in Table 2 . We used the 19th item of the BDI as an indirect indicator of disease severity. When the 19th item was compared between groups, there was no statistical difference (Mdn FMF = 0, Mdn Controls = 0, U = 490, P = 0.090).
A model was established that included statistically significant variables between the two groups. The variables included groups (FMF and healthy control groups), GRISS frequency and vaginismus subscales, BDI, BAI, and PAF. The Figure shows the described model. According to the model, the group variable was found to have an effect on the GRISS frequency and vaginismus subscale variables, independent of anxiety and depression levels. In addition, it had no direct effect on premenstrual syndrome, but it was observed to have an effect on total PAF score (increased level of anxiety). The group variable had no effect on depression, but depression scores had a significant effect on total PAF score. The values of the fitness of the model are CMIN = 9.129; DF = 9; CMIN/DF = 1.014; P = 0.425; GFI = 0.956; IFI = 0.999; CFI = 0.999; and RMSEA = 0.015.
Discussion
Our path model showed a perfect fit. One of the most important results obtained from our study is that FMF moderately increased the GRISS frequency and vaginismus subscale scores. Previous studies have shown that psychological factors caused by rheumatic disease can cause sexual dysfunction (12) . Similarly, other studies have suggested that rheumatic diseases can directly (28) or indirectly (29, 30) cause physical effects on sexual function (31) . Although it has been reported that autonomic neuropathy caused by amyloidosis may lead to impotence in men (32), there is not enough information about the direct effects of FMF on female sexual function in the literature. According to our model, anxiety and depression levels cannot explain the sexual dysfunction. Therefore, another psychological factor is probably responsible. It can be said that this psychological factor is anxiety sensitivity. FMF is a disease characterized by episodes of abdominal pain, which can adversely affect functionality (33, 34) . Patients might avoid situations that cause this pain (35) , and patients with FMF may exhibit avoidance or precautionary behaviors, believing that they can reduce or stop pain in this way. Some studies have suggested that exercise and emotional factors might increase episodes of pain in patients with FMF (36) . In addition, although the probability of incidence decreases after colchicine treatment (37), pelvic adhesions due to recurrent episodes of abdominal serositis and exploratory laparoscopy (38) can cause pain during sexual activity, or patients might worry that FMF attacks might be triggered during sexual activity. Therefore, patients might avoid sexual activity to prevent pain attacks. This hypothesis may be a distinct research topic.
The second important result of the model is that FMF has no direct effect on PMS, but it indirectly increased the total PAF score by increasing anxiety levels. The effects of FMF on anxiety levels and the effects of anxiety on PMS are strong. It has been shown that estrogens can inhibit interleukin 6 production and inhibition of this interleukin may indirectly ameliorate the inflammatory process (39) . Thus, menstruation can trigger pain attacks in patients with FMF (40) . As such, the expectation of a pain attack during menstruation might cause increased levels of anxiety (41) . Pain, including abdominal pain, is known to elicit anxiety (42) . Similar to our study, other studies have shown strong positive correlations between anxiety and PMS (43, 44) .
The reasons for the small sample size of this study are that the research was planned as a single-center study, the inclusion criteria were strict, and both FMF patients and healthy controls were reluctant to participate due to the questions regarding sexual function. However, despite the small sample size, for many variables, the effect size was moderate or high (especially anxiety), and the difference between groups was supported by path analysis. One of the limitations of the study is that all of the FMF patients were using colchicine, which might have caused sample bias. However, colchicine (used in the treatment of FMF) is generally well tolerated and there is no evidence of sexual side effects (45) , and no evidence was found in the literature, using several screening databases (PubMed, Science Direct, EBSCO), that colchicine has negative effects on sexual function or PMS. Another limitation of our study is the lack of a tool that directly measures the severity of FMF (such as frequency of episodes of abdominal pain). However, we tried to overcome this problem by using the 19th item of the BDI. It measures the perspective of the participants of their own health status in the last week. We found that there was no significant difference in perceived health between the two groups and concluded that clinical measurements were performed under ideal circumstances. Improving the quality of life in patients with FMF is as important as improving the symptoms associated with FMF. With drugs such as colchicine, the symptoms of FMF can be largely controlled, and long-term complications associated with FMF have been greatly reduced. However, psychiatric complications that adversely affect the quality of sexual and reproductive life are still observed in FMF patients. Therefore, it is extremely important that FMF patients be evaluated for psychiatric comorbidities such as sexual dysfunction and PMS. 
